pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 8·1 min read
save

Natalie Holles appointed CEO after Third Harmonic shutdown; Mark Alles steps down at ADC Biotech

May 8, 2026·read at Endpoints ↗Neutral

Natalie Holles quickly found a new role after the decision to wind down operations at Third Harmonic. She has taken over as chief executive, succeeding Elisabet de los Pinos.

At the same time, Mark Alles is handing over leadership responsibilities at ADC Biotech, signaling a transition in the company’s management.

These leadership moves highlight the fluid nature of executive positions in the biotech sector as companies adjust to changing strategic priorities.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech”

read at Endpoints ↗
88 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.
topics
Antibody-Drug Conjugate (ADC)3

related stories

  • Oct 5Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansionEndpoints
  • May 6Lonza looks to ride ADC wave with upcoming factory, workforce expansionEndpoints
  • May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive
  • May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive
  • May 6Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive